AI-generated analysis. Always verify with the original filing.
Relmada Therapeutics entered into a $160 million private placement for 29.5M common shares at $4.75 and pre-funded warrants for 4.2M shares at $4.749, closing March 11, 2026, with proceeds for working capital and R&D including NDV-01. Concurrently announced positive 12-month Phase 2 interim data for NDV-01 in high-risk NMIBC showing 76% CR rate overall and 80% in BCG-unresponsive patients.
Event Type
Disclosure
Mandatory
Variant
8-K
Entry into a Material Definitive Agreement. On March 9, 2026, Relmada Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purc
. The securities described above under Item 1.01 have not been registered under the Securities Act of 1933, as amended (the “Securities Act”). Based in part upo
of this Current Report on Form 8-K and in Exhibits 99.1, 99.2 and 99.3 attached hereto will not be treated as “filed” for the purposes of Section 18 of the Secu
. Other Events. On March 9, 2026, the Company announced 12-month interim data from its ongoing Phase 2 trial evaluating NDV-01 in patients with high-risk non-mu
. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 4.1 Form of Pre-Funded Warrant. 10.1* Form of Purchase Agreement, dated March 9, 2026,
Material Agreement